Linscomb & Williams Inc. increased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 36.9% in the 4th quarter, HoldingsChannel reports. The fund owned 4,756 shares of the biopharmaceutical company’s stock after acquiring an additional 1,281 shares during the period. Linscomb & Williams Inc.’s holdings in Bristol-Myers Squibb were worth $291,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of BMY. ProVise Management Group LLC lifted its stake in Bristol-Myers Squibb by 38.5% during the second quarter. ProVise Management Group LLC now owns 15,756 shares of the biopharmaceutical company’s stock valued at $877,000 after purchasing an additional 4,381 shares during the last quarter. RFG Advisory Group LLC lifted its stake in Bristol-Myers Squibb by 125.3% during the second quarter. RFG Advisory Group LLC now owns 9,961 shares of the biopharmaceutical company’s stock valued at $557,000 after purchasing an additional 5,539 shares during the last quarter. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. Decatur Capital Management Inc. acquired a new stake in Bristol-Myers Squibb during the second quarter valued at approximately $9,580,000. Finally, Intersect Capital LLC lifted its stake in Bristol-Myers Squibb by 8.5% during the second quarter. Intersect Capital LLC now owns 11,729 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 919 shares during the last quarter. Institutional investors and hedge funds own 70.57% of the company’s stock.
In related news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.
Shares of Bristol-Myers Squibb Co (BMY) opened at $65.47 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The company has a market cap of $109,089.20, a P/E ratio of 22.20, a P/E/G ratio of 2.08 and a beta of 0.98. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The business had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. research analysts forecast that Bristol-Myers Squibb Co will post 3.21 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a $0.40 dividend. The ex-dividend date is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 2.44%. Bristol-Myers Squibb’s payout ratio is 271.19%.
BMY has been the subject of several recent research reports. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price for the company. in a research note on Tuesday, January 16th. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Tuesday, December 5th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, January 19th. Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $66.30.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).